Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer.

Anti-cancer agents in medicinal chemistry - 1 Jan 2023

Wu Tingyu, Yu Jiawen, Wang Changyuan, Jin Yue, Zheng Xu, Chen Lixue, Ma Xiaodong, Sun Xiuli

Abstract excerpt

BACKGROUND: In-depth and clear mechanistic study is a prerequisite for new drugs to enter clinical research. METHODS: New chemical entity BY4008 was identified by our lab as a novel and highly potent EGFR and JAK3 dualtarget inhibitor. A cell-based test exhibited strong antiproliferative activities against SW620 and HCT116 colon cancer cells harboring KRAS mutation with IC50 of nanomolar potency. Furthermore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Janus Kinase 3

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35692150
DOI: 10.2174/1871520622666220609112816

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer.PMID 35692150Read ↗

Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells.Semantic proximity Read ↗

Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.Semantic proximity Read ↗

Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.Semantic proximity Read ↗

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read ↗

Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.Semantic proximity Read ↗

Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.Semantic proximity Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.Semantic proximity Read ↗

Berbamine as potential STING inhibitor For KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosisSemantic proximity Read ↗

A Novel N-heterocyclic Carbene Compound Exhibits Anticancer Properties by Inducing Apoptosis, Inhibiting Cell Migration, and Improving Standard Therapeutic Efficacy in Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.